MedPath

Remote Activity Monitored by Fitbit Charge 3 in Investigating Daily Step and Sleep Data in Participants With Head and Neck Cancer Undergoing Radiation Therapy

Not Applicable
Completed
Conditions
Head and Neck Carcinoma
Interventions
Device: Monitoring Device
Registration Number
NCT03489252
Lead Sponsor
Sidney Kimmel Cancer Center at Thomas Jefferson University
Brief Summary

This pilot trial studies remote activity monitored by Fitbit Charge 3 in investigating daily step and sleep data in participants with head and neck cancer who are undergoing radiation therapy. A wearable remote activity tracking device, such as the Fitbit Charge 3, may help to detect early signs of treatment or disease-related symptoms, improve quality of life, decrease emergency room visits, and decrease hospitalizations in participants with head and neck cancer.

Detailed Description

PRIMARY OBJECTIVES:

I. Determine compliance with remote activity monitoring (RAM) in patients receiving radiotherapy (RT) or chemoradiotherapy (CRT) for head and neck cancer (HNC).

SECONDARY OBJECTIVES:

I. Evaluate feasibility of recruitment to the Remote Activity Monitoring Pilot (RAMP).

II. Investigate patient acceptability of RAM. III. Evaluate compliance with electronic patient-reported outcomes (ePROs) in this patient population.

IV. Estimate the change in average daily steps associated with a one-unit change in health score as collected on ePRO analysis (analyze associations between RAM data and ePROs).

V. Investigate correlations among step data, quality of life (QOL), and emergency room (ER) visits/hospitalizations.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
41
Inclusion Criteria
  • Subjects have head and neck cancer as defined in history and physical
  • Patients are eligible to be treated with RT or CRT and plan to start treatment
  • Patients are capable of giving informed consent
  • Patients must be able to read and/or to speak English
  • Patients who are 18 years of age or older
  • Women of reproductive potential should have a negative serum or urine pregnancy test within the week prior to radiation CT planning scan
Read More
Exclusion Criteria
  • Patients who cannot read or speak English
  • Patients who are not candidates for RT/CRT treatment.
  • Women of childbearing potential who are pregnant or breastfeeding
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Device Feasibility (Fitbit Charge 3)Monitoring DeviceParticipants wear the Fitbit Charge 3 device from the time of CT simulation for RT planning throughout the entire RT course.
Primary Outcome Measures
NameTimeMethod
Percentage of time patients wear the Fitbit Charge 3 device (compliance)Through study completion, an average of 3 months

Daily compliance with remote activity monitoring (RAM) will be defined as wearing the device for 19/24 hours daily (80% daily use). Overall study period compliance will be defined as usage of the device for at least 70% of the days under observation where it should have been worn. The overall study period compliance rate along with a one-sided exact 95% confidence interval will be estimated.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Sidney Kimmel Cancer Center at Thomas Jefferson University

🇺🇸

Philadelphia, Pennsylvania, United States

Sidney Kimmel Cancer Center at Thomas Jefferson University
🇺🇸Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath